283 related articles for article (PubMed ID: 32057269)
1. Targeted synthetic pharmacotherapy for psoriatic arthritis: state of the art.
Caso F; Navarini L; Ruscitti P; Chimenti MS; Girolimetto N; Del Puente A; Giacomelli R; Scarpa R; Costa L
Expert Opin Pharmacother; 2020 May; 21(7):785-796. PubMed ID: 32057269
[TBL] [Abstract][Full Text] [Related]
2. Small molecule therapy for managing moderate to severe psoriatic arthritis.
Costa L; Del Puente A; Peluso R; Tasso M; Caso P; Chimenti MS; Sabbatino V; Girolimetto N; Benigno C; Bertolini N; Del Puente A; Perricone R; Scarpa R; Caso F
Expert Opin Pharmacother; 2017 Oct; 18(15):1557-1567. PubMed ID: 28891341
[TBL] [Abstract][Full Text] [Related]
3. Novel Oral Therapies for Psoriasis and Psoriatic Arthritis.
Yiu ZZ; Warren RB
Am J Clin Dermatol; 2016 Jun; 17(3):191-200. PubMed ID: 26923915
[TBL] [Abstract][Full Text] [Related]
4. A novel treatment for psoriatic arthritis: Janus kinase inhibitors.
Chen M; Dai SM
Chin Med J (Engl); 2020 Apr; 133(8):959-967. PubMed ID: 32209886
[TBL] [Abstract][Full Text] [Related]
5. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, filgotinib and peficitinib as monotherapy for active rheumatoid arthritis.
Ho Lee Y; Gyu Song G
J Clin Pharm Ther; 2020 Aug; 45(4):674-681. PubMed ID: 32495356
[TBL] [Abstract][Full Text] [Related]
6. An evaluation of tofacitinib for the treatment of psoriatic arthritis.
Abdulrahim H; Sharlala H; Adebajo AO
Expert Opin Pharmacother; 2019 Nov; 20(16):1953-1960. PubMed ID: 31456440
[No Abstract] [Full Text] [Related]
7. Tofacitinib for the treatment of psoriasis and psoriatic arthritis.
Berekmeri A; Mahmood F; Wittmann M; Helliwell P
Expert Rev Clin Immunol; 2018 Sep; 14(9):719-730. PubMed ID: 30118353
[TBL] [Abstract][Full Text] [Related]
8. Drug safety evaluation of apremilast for treating psoriatic arthritis.
Busa S; Kavanaugh A
Expert Opin Drug Saf; 2015 Jun; 14(6):979-85. PubMed ID: 25827658
[TBL] [Abstract][Full Text] [Related]
9. Novel treatments with small molecules in psoriatic arthritis.
Hansen RB; Kavanaugh A
Curr Rheumatol Rep; 2014; 16(9):443. PubMed ID: 25027606
[TBL] [Abstract][Full Text] [Related]
10. Apremilast: a PDE4 inhibitor for the treatment of psoriatic arthritis.
Abdulrahim H; Thistleton S; Adebajo AO; Shaw T; Edwards C; Wells A
Expert Opin Pharmacother; 2015 May; 16(7):1099-108. PubMed ID: 25864487
[TBL] [Abstract][Full Text] [Related]
11. Comparison of the Efficacy and Safety of Tofacitinib and Apremilast in Patients with Active Psoriatic Arthritis: A Bayesian Network Meta-Analysis of Randomized Controlled Trials.
Song GG; Lee YH
Clin Drug Investig; 2019 May; 39(5):421-428. PubMed ID: 30806969
[TBL] [Abstract][Full Text] [Related]
12. New targets in psoriatic arthritis.
Braun J
Rheumatology (Oxford); 2016 Dec; 55(suppl 2):ii30-ii37. PubMed ID: 27856658
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib in active rheumatoid arthritis refractory to biologic disease-modifying antirheumatic drugs.
Lee YH; Song GG
Z Rheumatol; 2021 May; 80(4):379-392. PubMed ID: 32367211
[TBL] [Abstract][Full Text] [Related]
14. [Role of janus kinase inhibitors in the treatment of rheumatic diseases].
Krüger K
Internist (Berl); 2019 Nov; 60(11):1215-1220. PubMed ID: 31486859
[TBL] [Abstract][Full Text] [Related]
15. JAK inhibitors, psoriatic arthritis, and axial spondyloarthritis: a critical review of clinical trials.
Keeling S; Maksymowych WP
Expert Rev Clin Immunol; 2021 Jul; 17(7):701-715. PubMed ID: 33944642
[TBL] [Abstract][Full Text] [Related]
16. The efficacy and safety of different Janus kinase inhibitors as monotherapy in rheumatoid arthritis: A Bayesian network meta-analysis.
Qu B; Zhao F; Song Y; Zhao J; Yao Y; Chen Y; Liao R; Fu L
PLoS One; 2024; 19(6):e0305621. PubMed ID: 38905267
[TBL] [Abstract][Full Text] [Related]
17. Comparative study of the efficacy and safety of tofacitinib, baricitinib, upadacitinib, and filgotinib versus methotrexate for disease-modifying antirheumatic drug-naïve patients with rheumatoid arthritis.
Sung YK; Lee YH
Z Rheumatol; 2021 Nov; 80(9):889-898. PubMed ID: 32970188
[TBL] [Abstract][Full Text] [Related]
18. Comparative Efficacy of JAK Inhibitors for Moderate-To-Severe Rheumatoid Arthritis: A Network Meta-Analysis.
Pope J; Sawant R; Tundia N; Du EX; Qi CZ; Song Y; Tang P; Betts KA
Adv Ther; 2020 May; 37(5):2356-2372. PubMed ID: 32297280
[TBL] [Abstract][Full Text] [Related]
19. Clinical efficacy of launched JAK inhibitors in rheumatoid arthritis.
Taylor PC
Rheumatology (Oxford); 2019 Feb; 58(Suppl 1):i17-i26. PubMed ID: 30806707
[TBL] [Abstract][Full Text] [Related]
20. Recent developments for new investigational JAK inhibitors in psoriatic arthritis.
Caso F; Costa L; Triggianese P; Maione F; Bertolini N; Vastarella M; Chimenti MS; Tasso M
Expert Opin Investig Drugs; 2023 May; 32(5):361-371. PubMed ID: 37096862
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]